In conclusion, for the first time this study demonstrates that TLR4 expressed on PC cell surfaces functions as a receptor of PAUF to mediate its metastasis-promoting effects, which are exclusively through the MyD88/NF-κB signaling pathway. This study also suggests TLR4 as a potential biomarker for identification of optimal patients, and a new therapeutic target to treat PC. Anti-PAUF antibody used in this study is currently evaluated by clinical trials in France, Spain, and US FDA.
almost 3 years ago
IO biomarker
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • TLR4 (Toll Like Receptor 4) • ZG16B (Zymogen Granule Protein 16B)
These findings indicate that tumor necrosis is associated with low TLR4 expression in cancer cells and that low TLR4 expression correlates with a strong systemic inflammatory response. The low TLR2 expression in normal mucosa and its association with systemic inflammation suggest that the normal mucosa may reflect or contribute to the systemic inflammatory response.
IHC staining of inflammasome activators using TMA may allow better characterization of molecular pathways contributing the MDS pathogenesis. A correlation was seen between expression of antigens known to be increased downstream of NLRP3 inflammasome activation. Survival was increased in patients with low CPLA2 expression, high beta-catenin expression, and low TLR4 expression.
over 4 years ago
Clinical
|
CD33 (CD33 Molecule) • S100A9 (S100 Calcium Binding Protein A9) • TLR4 (Toll Like Receptor 4) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3)